Targeted therapy using engineered antibodies for pancreatic cancer
Engineered anti-PSCA antibodies for immunoPET and targeted therapy of pancreatic cancer
This study is testing a new type of treatment for advanced pancreatic cancer that uses specially designed antibodies to target a specific protein found in many pancreatic tumors, aiming to make the treatment more effective while protecting healthy organs from radiation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-11005732 on NIH RePORTER |
What this research studies
This research focuses on developing engineered antibodies that target the Prostate Stem Cell Antigen (PSCA), which is found in a high percentage of pancreatic cancer cases. By utilizing a specialized antibody fragment designed for effective delivery of therapeutic radionuclides, the research aims to improve treatment outcomes for patients with advanced pancreatic cancer. The approach includes biodistribution studies in mouse models to confirm targeting and clearance, followed by efficacy testing in various pancreatic cancer models. This innovative method seeks to minimize radiation exposure to healthy organs while maximizing treatment effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with advanced pancreatic cancer who express the Prostate Stem Cell Antigen.
Not a fit: Patients with pancreatic cancer who do not express the Prostate Stem Cell Antigen may not benefit from this targeted therapy.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with advanced pancreatic cancer.
How similar studies have performed: Previous research has shown promising results with targeted radionuclide therapies in other cancer types, indicating potential for success with this novel approach in pancreatic cancer.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Wu, Anna M — Beckman Research Institute/city of Hope
- Study coordinator: Wu, Anna M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.